(Q42608727)

English

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals

scientific article published on 12 October 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

multicenter clinical trial

0 references

object named as

Bobby P Smyth

9

0 references

object named as

John Strang

12

0 references

author name string

Leslie Amass

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Vilma Pukeleviciene

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Emilis Subata

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

António Rocha Almeida

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Maria Chiara Pieri

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Pietro D'Egidio

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Zdenka Stankova

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

António Costa

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Slavko Sakoman

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Yan Wei

11

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

language of work or name

0 references

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

142-151

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Global overview of injecting drug use and HIV infection among injecting drug users.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine use: the international experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine: how to use it right

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Trends in prescribing of buprenorphine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Injecting misuse of buprenorphine among French drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Recent evolution in opiate dependence in France during generalisation of maintenance treatments

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Relative bioavailability of different buprenorphine formulations under chronic dosing conditions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Pharmacokinetics of the combination tablet of buprenorphine and naloxone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Effects of buprenorphine/naloxone in opioid-dependent humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Home buprenorphine/naloxone induction in primary care

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Factors associated with complicated buprenorphine inductions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Consensus statement on office-based treatment of opioid dependence using buprenorphine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine: a controlled clinical trial in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Comparison of buprenorphine and methadone in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Buprenorphine and naloxone interactions in opiate-dependent volunteers*

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Two New Rating Scales for Opiate Withdrawal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03577.X

21 January 2018

Identifiers

10.1111/J.1360-0443.2011.03577.X

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42608727&oldid=1962782537"